NCT04313894 (WHAMKO) is a Phase 2 clinical trial of Wharton Jelly Originated Mesencimal Stem Cell in Stem Cell, sponsored by TC Erciyes University.

Who is sponsoring NCT04313894?

NCT04313894 is sponsored by TC Erciyes University.

What drugs are being tested in NCT04313894?

Interventions in NCT04313894: Wharton Jelly Originated Mesencimal Stem Cell.

What condition does NCT04313894 study?

NCT04313894 studies Stem Cell, Gonarthrosis.

Is NCT04313894 still recruiting?

NCT04313894 is currently status unknown. Last updated 18 March 2020.

Last reviewed 2020-03-18 · How we verify

NCT04313894: WHAMKO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

WHARTON JELLY ORIGINATED MESENCHIAL STEM CELL in GONARTHROSIS

Status unknown Phase 2 Last updated 18 March 2020

What this trial tests

Phase 2 trial testing Wharton Jelly Originated Mesencimal Stem Cell in Stem Cell in 11 participants. Status unknown.

Timeline

1 January 2019

Primary endpoint
31 December 2019

31 December 2020

Quick facts

Lead sponsor	TC Erciyes University
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	11
Start date	1 January 2019
Primary completion	31 December 2019
Estimated completion	31 December 2020
Sites	1 location across Turkey (Türkiye)

Drugs / interventions tested

Wharton Jelly Originated Mesencimal Stem Cell — full drug profile →

Conditions studied

Stem Cell — all drugs for Stem Cell →
Gonarthrosis — all drugs for Gonarthrosis →

Sponsor

TC Erciyes University

Who can join

Adults 60 to 65, any sex, with Stem Cell or Gonarthrosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Osteoarthritis (OA) is a progressive disease characterized by degeneration of the joint cartilage, which is involved in the immune system leading to proinflammatory cytokine and metalloproteinase release. Knee osteoarthritis is the most common form. The healing is very slow and the damage is not fully recovered, so the degeneration process continues and no treatment modalities completely remove this process. Various methods are used in the treatment of OA and total joint replacement is performed in the patients with OA recently. Ten patients with Kellgren-Lawrence grade II-III knee OA who had been applied for knee pain and received conservative treatment for 6 months and had no benefit will be taken to study. Patients will be assessed 7 (V1-7) times during the study. Clinical, immunologic and radiological treatment effectiveness and clinical improvement will be evaluated at the beginning of the treatment and in all follow-up patients participating in the study.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Wharton's jelly and osteoarthritis of the knee.
Aratikatla A, Maffulli N, Gupta M, Potti IA, et al · · 2024 · cited 18× · PMID 38061765 · DOI 10.1093/bmb/ldad030
Challenges and opportunities of pharmacological interventions for osteoarthritis: A review of current clinical trials and developments.
Vrouwe JPM, Burggraaf J, Kloppenburg M, Stuurman FE. · · 2021 · cited 16× · PMID 36474768 · DOI 10.1016/j.ocarto.2021.100212
Assessment of clinical, biochemical, and radiological outcomes following intra-articular injection of Wharton jelly-derived mesenchymal stromal cells in patients with knee osteoarthritis: A prospective clinical study.
Günay AE, Karaman I, Guney A, Karaman ZF, et al · · 2022 · cited 11× · PMID 36123928 · DOI 10.1097/md.0000000000030628

Verify or expand the search:

Other recruiting trials for Stem Cell

Currently open trials in the same condition.

NCT07227883 — Secretome Treatment for Facial Rejuvenation · EARLY_PHASE1 · recruiting
NCT06564740 — Stem Cell Applications in Biliary Atresia Patients · NA · recruiting
NCT06004063 — Safety, Tolerability, and Efficacy of Enteral Nutrition Versus Standard of Care Nutrition in Hematopoietic Stem Cell Tra · NA · recruiting
NCT03947450 — Autologous Volar Fibroblast Injection Into the Stump Site of Amputees · Phase 2 · recruiting

Other TC Erciyes University trials

Trials by the same sponsor.

NCT07007858 — Effects of High-Velocity Passive Stretch on Spasticity, Function, and Muscle Structure in Spastic CP Children · NA · enrolling by invitation
NCT07529964 — MMP-2/3 and Periapical Healing Outcomes · not yet recruiting
NCT07526831 — Comparison of the Analgesic Efficacy of Adductor Canal Block and Combined Adductor Canal Block Plus IPACK Block in Knee · recruiting
NCT07371806 — EFFETCS OF MİNDFULNESS-BASED STRESS REDUCTION İN WOMEN WİTH CORONARY ARTERY DİSEASE · NA · not yet recruiting
NCT07499947 — Predicting Spinal Hypotension in Cesarean Section · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04313894 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by TC Erciyes University
Last refreshed: 18 March 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04313894.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing